Because it's virtually de-risked. Prior to that there was no real certainty of approval realistically. It was still largely a binary events and we know how binary events go in this space. The market sold off prior to approval in case of the rejection, which happened.
Given that it's just the packaging, you'd think this would now be a non-issue going forward.
The product is clearly a stand out amongst what is out there. The management team is world class. Vinnie sold Anacor to pfizer for $5.2 billion. He's head and shoulders above the rest of the bio management teams on the ASX.
You also need to look at the comparative market caps of CU6 and MSB.
Botanix is severely lagging these and has a product a lot further in the piece.
The market is not pricing a lot of upside in here. We will re-rate heavily again shortly.
All in my humble opinion of course.
Because it's virtually de-risked. Prior to that there was no...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $346.5M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.5¢ | $556.8K | 2.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 188599 | 5 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
21.8¢ |
Change
0.000 ( 1.09 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.0¢ | 21.5¢ | 1397313 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| BOT (ASX) Chart |